Fatality and interferon α for malignant melanoma

Lancet

Volumn 352, Issue 9138, 1998, Pages 1443-1444

  Carson, John J ^a   Gold, Louis H ^b   Barton, Amy B ^a   Biss, Roger T ^a  

^a St Peter's Hospital Albany   (United States)

^b Pulmon and Critical Care Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG FATALITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; PRIORITY JOURNAL; SHOCK;

EID: 0032585283     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)61266-4     Document Type: Article

References (4)

1. 1 Kirkwood JM, Strawderman MH, Emstoff MS, et al. Interferon alpha 2b adjuvant therapy of high risk cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
2. 2 Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994; 10: 115-50.
3. 3 Cohen MC, Huberman MS, Nesto RW. Recombinant alpha2 interferon related cardiomyopathy. Am J Med 1988; 85: 549-51.
4. 4 Reinhold U, Hartyl C, Hering R, Hoeft A, Kreysel H. Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alpha in malignant melanoma. Lancet 1997; 349: 540-41.